Publication Cover
Hemoglobin
international journal for hemoglobin research
Volume 35, 2011 - Issue 3
203
Views
18
CrossRef citations to date
0
Altmetric
PROCEEDINGS 19th ICOC November 2009, London, UK

Sequential Alternating Deferiprone And Deferoxamine Treatment Compared To Deferiprone Monotherapy: Main Findings And Clinical Follow-Up Of A Large Multicenter Randomized Clinical Trial In -Thalassemia Major Patients

, , , , , , , , , , , , , , , , , , , , , , , , & show all
Pages 206-216 | Published online: 20 May 2011

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Adriana Ceci, Rosa Conte, Antonella Didio, Donato Bonifazi, Mariagrazia Felisi, Viviana Giannuzzi & Fedele Bonifazi. (2019) An overview of the efficacy and safety of deferiprone in paediatric patients with congenital haemoglobinopathies and chronic iron overload. Expert Opinion on Orphan Drugs 7:4, pages 181-197.
Read now

Articles from other publishers (15)

Louise J Geneen, Carolyn Dorée & Lise J Estcourt. (2023) Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia. Cochrane Database of Systematic Reviews 2023:3.
Crossref
Christine C. Hsu, Nizar H. Senussi, Kleber Y. Fertrin & Kris V. Kowdley. (2022) Iron overload disorders. Hepatology Communications 6:8, pages 1842-1854.
Crossref
Andrew Binding, Richard Ward, George Tomlinson & Kevin H. M. Kuo. (2019) Deferiprone exerts a dose‐dependent reduction of liver iron in adults with iron overload. European Journal of Haematology 103:2, pages 80-87.
Crossref
Nancy F. Olivieri, Amir Sabouhanian & Brenda L. Gallie. (2019) Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox. PLOS ONE 14:2, pages e0211942.
Crossref
Patricia M Fortin, Sheila A Fisher, Karen V Madgwick, Marialena Trivella, Sally Hopewell, Carolyn Doree & Lise J Estcourt. (2018) Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia. Cochrane Database of Systematic Reviews 2018:5.
Crossref
Robert Crichton. 2016. Iron Metabolism. Iron Metabolism 376 417 .
Somayeh Kalanaky, Maryam Hafizi, Sepideh Safari, Kazem Mousavizadeh, Mahboubeh Kabiri, Alireza Farsinejad, Saideh Fakharzadeh & Mohammad Hassan Nazaran. (2016) TLc-A, the leading nanochelating-based nanochelator, reduces iron overload in vitro and in vivo. International Journal of Hematology 103:3, pages 274-282.
Crossref
Raffaella Origa. (2014) Combination Therapies in Iron Chelation. Thalassemia Reports 4:3, pages 4862.
Crossref
Maria Marsella & Caterina Borgna-Pignatti. (2014) Transfusional Iron Overload and Iron Chelation Therapy in Thalassemia Major and Sickle Cell Disease. Hematology/Oncology Clinics of North America 28:4, pages 703-727.
Crossref
Vip Viprakasit & Worapant Kriengsoontornkij. 2014. A worldwide yearly survey of new data in adverse drug reactions and interactions. A worldwide yearly survey of new data in adverse drug reactions and interactions 419 433 .
Sujian Xia, Weidong Zhang, Liting Huang & Hong Jiang. (2013) Comparative Efficacy and Safety of Deferoxamine, Deferiprone and Deferasirox on Severe Thalassemia: A Meta-Analysis of 16 Randomized Controlled Trials. PLoS ONE 8:12, pages e82662.
Crossref
Sheila A Fisher, Susan J Brunskill, Carolyn Doree, Onima Chowdhury, Sarah Gooding & David J Roberts. (2013) Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database of Systematic Reviews.
Crossref
Sheila A Fisher, Susan J Brunskill, Carolyn Doree, Sarah Gooding, Onima Chowdhury & David J Roberts. (2013) Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. Cochrane Database of Systematic Reviews.
Crossref
Dennis J. Cada, Terri L. Levien & Danial E. Baker. (2012) Deferiprone. Hospital Pharmacy 47:2, pages 129-136.
Crossref
V. S. Nadarajan. (2011) Modern management of thalassemia. ISBT Science Series 6:2, pages 432-437.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.